

23 February 2022

Drugs Used in the Treatment of Lung Cancer

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with drugs listed?

Please see information below, as available from the Regional Information System Oncology & Haematology (RISOH) - November 2021 – January 2022

Afatinib	1
Alectinib	2
Atezolizumab monotherapy	2
Atezolizumab with chemotherapy	0
Bevacizumab	0
Brigatinib	0
Ceritinib	0
Crizotinib	1
Dacomitinib	0
Dabrafenib with Trametinib	0
Docetaxel monotherapy or combination with Carboplatin/Cisplatin	0
Durvalumab	1
Erlotinib	0
Gefitinib	1
Gemcitabine	0
Lorlatinib	0
Nintedanib with Docetaxel	0
Nivolumab	0
Osimertinib	10
Paclitaxel	0
Pembrolizumab monotherapy	24
Pembrolizumab with chemotherapy	9
Pemetrexed with Carboplatin/Cisplatin	2
Tepotinib	0
Vinorelbine with Carboplatin/Cisplatin	2
Any other active systemic anti-cancer therapy (SACT) Gemcitabine&Carboplatin	4
Palliative care only	Not available via RISOH

23 February 2022

Q2. In the past 3 months, how many patients were treated for squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs?

Atezolizumab monotherapy	0
Atezolizumab with chemotherapy	0
Durvalumab	1
Gemcitabine + Carboplatin	4
Nivolumab	0
Osimertinib	0
Paclitaxel	0
Pembrolizumab (Keytruda) Mono	5
Pembrolizumab (Keytruda) with Chemotherapy	3
Other active systemic anti-cancer therapy (SACT)	
Carboplatin/Vinorelbine	5
Cisplatin/Vinorelbine	7
Palliative care only	Not available via RISOH